Global Chickenpox Vaccine

Chickenpox Vaccine Comprehensive Study by Type (Monovalent Vaccine, Combination Vaccine), Application (Hospitals, Clinics, Laboratories), End User (Children, Adults) Players and Region - Global Market Outlook to 2028

Chickenpox Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Chickenpox Vaccine Market Scope
Chickenpox is very common across the world for which there is a chickenpox vaccine given as a shot that can protect almost everyone from chickenpox disease as it is caused by the virus called varicella-zoster and is made from the live but weakened or attenuated virus. It has greatly reacted and reduced the number of people from catching chickenpox, two doses of the chickenpox vaccine are about 94% effective. Most of the people who get the shot of vaccines don't get chickenpox and those who do generally get the milder level of the disease. It is widely available in public healthcare clinics, and hospitals, between 70% and 90% of people vaccinated will be completely immune to chickenpox.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledMerck & Co., Inc. (United States), Biken Group (Japan), Green Cross Health Ltd. (New Zealand), GlaxoSmithKline plc. (United Kingdom), Novo (India), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan) and The Takeda Pharmaceutical Company Limited (Japan)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. The players explore new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Merck & Co., Inc. (United States), Biken Group (Japan), Green Cross Health Ltd. (New Zealand), GlaxoSmithKline plc. (United Kingdom), Novo (India), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan) and The Takeda Pharmaceutical Company Limited (Japan) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Chickenpox Vaccine market by Type , by Application (Hospitals, Clinics and Laboratories) and Region with country level break-up.

On the basis of geography, the market of Chickenpox Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In July 2022, South Korean biotech company GC LabCell signed a definitive merger agreement with South Korean varicella vaccine biotech company GC Cell Corporation. The transaction brings together two leading South Korean biopharmaceutical companies with complementary portfolios, a strong comprehensive cell therapy R&D pipeline, and state-of-the-art manufacturing capabilities to accelerate growth and accelerate prosperity.
In August 2020, during the pandemic, GSK announced the commencement of a DTC campaign for the Shingrix vaccine aimed toward the older population for varicella-zoster virus inoculation.
"The first chickenpox vaccine was licensed by the Food and Drug Administration in 1995 and is widely available in private doctors' offices and public health clinics. A combination of measles, mumps, rubella, and varicella (MMRV) vaccine was licensed in the United States in 2005 for use among healthy children aged 12 months-12 years. All healthy children 12 months through 12 years of age should have two doses of the chickenpox vaccine, administered at least 3 months apart. Children who have evidence of immunity to varicella do not need the vaccine. People 13 years of age and older who do not have evidence of immunity should get two doses of the vaccine 4 to 8 weeks apart. Chickenpox vaccination is especially important for certain groups of susceptible adults."

Influencing Trend:
Continuous Research and Development in Chickenpox Vaccination

Market Growth Drivers:
Growing Health Awareness Across the World, Need for Preventive Vaccination from Contagious Diseases and Stringent Regulatory Guidelines Regarding Chickenpox

Challenges:
High Cost of Vaccines

Restraints:
Side Effects Like Pain, Swelling, Redness, and Low Fever are Associated with Chickenpox Vaccine

Opportunities:
Awareness about Chickenpox and the Importance of Receiving the Vaccination in Rural regions of the Countries

Key Target Audience
Chickenpox Vaccine Manufacturers, Chickenpox Vaccine International Traders, Chickenpox Vaccine Distributors and Suppliers, Research and Development Institutes, Potential Investors, Industry Associations, Regulatory Bodies, Upstream and Downstream Buyers and Others

Report Objectives / Segmentation Covered

By Type
  • Monovalent Vaccine
  • Combination Vaccine
By Application
  • Hospitals
  • Clinics
  • Laboratories
By End User
  • Children
  • Adults

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Health Awareness Across the World
      • 3.2.2. Need for Preventive Vaccination from Contagious Diseases
      • 3.2.3. Stringent Regulatory Guidelines Regarding Chickenpox
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Vaccines
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development in Chickenpox Vaccination
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chickenpox Vaccine, by Type, Application, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chickenpox Vaccine (Value)
      • 5.2.1. Global Chickenpox Vaccine by: Type (Value)
        • 5.2.1.1. Monovalent Vaccine
        • 5.2.1.2. Combination Vaccine
      • 5.2.2. Global Chickenpox Vaccine by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Laboratories
      • 5.2.3. Global Chickenpox Vaccine by: End User (Value)
        • 5.2.3.1. Children
        • 5.2.3.2. Adults
      • 5.2.4. Global Chickenpox Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Chickenpox Vaccine (Volume)
      • 5.3.1. Global Chickenpox Vaccine by: Type (Volume)
        • 5.3.1.1. Monovalent Vaccine
        • 5.3.1.2. Combination Vaccine
      • 5.3.2. Global Chickenpox Vaccine by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Laboratories
      • 5.3.3. Global Chickenpox Vaccine by: End User (Volume)
        • 5.3.3.1. Children
        • 5.3.3.2. Adults
      • 5.3.4. Global Chickenpox Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Chickenpox Vaccine (Price)
      • 5.4.1. Global Chickenpox Vaccine by: Type (Price)
  • 6. Chickenpox Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biken Group (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Green Cross Health Ltd. (New Zealand)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. The Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Chickenpox Vaccine Sale, by Type, Application, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chickenpox Vaccine (Value)
      • 7.2.1. Global Chickenpox Vaccine by: Type (Value)
        • 7.2.1.1. Monovalent Vaccine
        • 7.2.1.2. Combination Vaccine
      • 7.2.2. Global Chickenpox Vaccine by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Laboratories
      • 7.2.3. Global Chickenpox Vaccine by: End User (Value)
        • 7.2.3.1. Children
        • 7.2.3.2. Adults
      • 7.2.4. Global Chickenpox Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Chickenpox Vaccine (Volume)
      • 7.3.1. Global Chickenpox Vaccine by: Type (Volume)
        • 7.3.1.1. Monovalent Vaccine
        • 7.3.1.2. Combination Vaccine
      • 7.3.2. Global Chickenpox Vaccine by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Laboratories
      • 7.3.3. Global Chickenpox Vaccine by: End User (Volume)
        • 7.3.3.1. Children
        • 7.3.3.2. Adults
      • 7.3.4. Global Chickenpox Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Chickenpox Vaccine (Price)
      • 7.4.1. Global Chickenpox Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chickenpox Vaccine: by Type(USD Million)
  • Table 2. Chickenpox Vaccine Monovalent Vaccine , by Region USD Million (2017-2022)
  • Table 3. Chickenpox Vaccine Combination Vaccine , by Region USD Million (2017-2022)
  • Table 4. Chickenpox Vaccine: by Application(USD Million)
  • Table 5. Chickenpox Vaccine Hospitals , by Region USD Million (2017-2022)
  • Table 6. Chickenpox Vaccine Clinics , by Region USD Million (2017-2022)
  • Table 7. Chickenpox Vaccine Laboratories , by Region USD Million (2017-2022)
  • Table 8. Chickenpox Vaccine: by End User(USD Million)
  • Table 9. Chickenpox Vaccine Children , by Region USD Million (2017-2022)
  • Table 10. Chickenpox Vaccine Adults , by Region USD Million (2017-2022)
  • Table 11. South America Chickenpox Vaccine, by Country USD Million (2017-2022)
  • Table 12. South America Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 13. South America Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 14. South America Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 15. Brazil Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 16. Brazil Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 17. Brazil Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 18. Argentina Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 19. Argentina Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 20. Argentina Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 21. Rest of South America Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 22. Rest of South America Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 23. Rest of South America Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 24. Asia Pacific Chickenpox Vaccine, by Country USD Million (2017-2022)
  • Table 25. Asia Pacific Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 26. Asia Pacific Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 27. Asia Pacific Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 28. China Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 29. China Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 30. China Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 31. Japan Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 32. Japan Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 33. Japan Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 34. India Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 35. India Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 36. India Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 37. South Korea Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 38. South Korea Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 39. South Korea Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 40. Taiwan Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 41. Taiwan Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 42. Taiwan Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 43. Australia Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 44. Australia Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 45. Australia Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 46. Rest of Asia-Pacific Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 49. Europe Chickenpox Vaccine, by Country USD Million (2017-2022)
  • Table 50. Europe Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 51. Europe Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 52. Europe Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 53. Germany Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 54. Germany Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 55. Germany Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 56. France Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 57. France Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 58. France Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 59. Italy Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 60. Italy Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 61. Italy Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 62. United Kingdom Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 63. United Kingdom Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 64. United Kingdom Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 65. Netherlands Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 66. Netherlands Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 67. Netherlands Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 68. Rest of Europe Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 69. Rest of Europe Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 70. Rest of Europe Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 71. MEA Chickenpox Vaccine, by Country USD Million (2017-2022)
  • Table 72. MEA Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 73. MEA Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 74. MEA Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 75. Middle East Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 76. Middle East Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 77. Middle East Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 78. Africa Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 79. Africa Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 80. Africa Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 81. North America Chickenpox Vaccine, by Country USD Million (2017-2022)
  • Table 82. North America Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 83. North America Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 84. North America Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 85. United States Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 86. United States Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 87. United States Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 88. Canada Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 89. Canada Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 90. Canada Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 91. Mexico Chickenpox Vaccine, by Type USD Million (2017-2022)
  • Table 92. Mexico Chickenpox Vaccine, by Application USD Million (2017-2022)
  • Table 93. Mexico Chickenpox Vaccine, by End User USD Million (2017-2022)
  • Table 94. Chickenpox Vaccine Sales: by Type(K Units)
  • Table 95. Chickenpox Vaccine Sales Monovalent Vaccine , by Region K Units (2017-2022)
  • Table 96. Chickenpox Vaccine Sales Combination Vaccine , by Region K Units (2017-2022)
  • Table 97. Chickenpox Vaccine Sales: by Application(K Units)
  • Table 98. Chickenpox Vaccine Sales Hospitals , by Region K Units (2017-2022)
  • Table 99. Chickenpox Vaccine Sales Clinics , by Region K Units (2017-2022)
  • Table 100. Chickenpox Vaccine Sales Laboratories , by Region K Units (2017-2022)
  • Table 101. Chickenpox Vaccine Sales: by End User(K Units)
  • Table 102. Chickenpox Vaccine Sales Children , by Region K Units (2017-2022)
  • Table 103. Chickenpox Vaccine Sales Adults , by Region K Units (2017-2022)
  • Table 104. South America Chickenpox Vaccine Sales, by Country K Units (2017-2022)
  • Table 105. South America Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 106. South America Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 107. South America Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 108. Brazil Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 109. Brazil Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 110. Brazil Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 111. Argentina Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 112. Argentina Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 113. Argentina Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 114. Rest of South America Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 115. Rest of South America Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 116. Rest of South America Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 117. Asia Pacific Chickenpox Vaccine Sales, by Country K Units (2017-2022)
  • Table 118. Asia Pacific Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 119. Asia Pacific Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 120. Asia Pacific Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 121. China Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 122. China Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 123. China Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 124. Japan Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 125. Japan Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 126. Japan Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 127. India Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 128. India Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 129. India Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 130. South Korea Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 131. South Korea Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 132. South Korea Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 133. Taiwan Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 134. Taiwan Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 135. Taiwan Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 136. Australia Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 137. Australia Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 138. Australia Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 139. Rest of Asia-Pacific Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 140. Rest of Asia-Pacific Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 141. Rest of Asia-Pacific Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 142. Europe Chickenpox Vaccine Sales, by Country K Units (2017-2022)
  • Table 143. Europe Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 144. Europe Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 145. Europe Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 146. Germany Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 147. Germany Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 148. Germany Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 149. France Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 150. France Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 151. France Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 152. Italy Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 153. Italy Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 154. Italy Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 155. United Kingdom Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 156. United Kingdom Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 157. United Kingdom Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 158. Netherlands Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 159. Netherlands Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 160. Netherlands Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 161. Rest of Europe Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 162. Rest of Europe Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 163. Rest of Europe Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 164. MEA Chickenpox Vaccine Sales, by Country K Units (2017-2022)
  • Table 165. MEA Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 166. MEA Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 167. MEA Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 168. Middle East Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 169. Middle East Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 170. Middle East Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 171. Africa Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 172. Africa Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 173. Africa Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 174. North America Chickenpox Vaccine Sales, by Country K Units (2017-2022)
  • Table 175. North America Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 176. North America Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 177. North America Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 178. United States Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 179. United States Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 180. United States Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 181. Canada Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 182. Canada Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 183. Canada Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 184. Mexico Chickenpox Vaccine Sales, by Type K Units (2017-2022)
  • Table 185. Mexico Chickenpox Vaccine Sales, by Application K Units (2017-2022)
  • Table 186. Mexico Chickenpox Vaccine Sales, by End User K Units (2017-2022)
  • Table 187. Chickenpox Vaccine: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Chickenpox Vaccine: by Type(USD Million)
  • Table 197. Chickenpox Vaccine Monovalent Vaccine , by Region USD Million (2023-2028)
  • Table 198. Chickenpox Vaccine Combination Vaccine , by Region USD Million (2023-2028)
  • Table 199. Chickenpox Vaccine: by Application(USD Million)
  • Table 200. Chickenpox Vaccine Hospitals , by Region USD Million (2023-2028)
  • Table 201. Chickenpox Vaccine Clinics , by Region USD Million (2023-2028)
  • Table 202. Chickenpox Vaccine Laboratories , by Region USD Million (2023-2028)
  • Table 203. Chickenpox Vaccine: by End User(USD Million)
  • Table 204. Chickenpox Vaccine Children , by Region USD Million (2023-2028)
  • Table 205. Chickenpox Vaccine Adults , by Region USD Million (2023-2028)
  • Table 206. South America Chickenpox Vaccine, by Country USD Million (2023-2028)
  • Table 207. South America Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 208. South America Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 209. South America Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 210. Brazil Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 211. Brazil Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 212. Brazil Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 213. Argentina Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 214. Argentina Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 215. Argentina Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 216. Rest of South America Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 217. Rest of South America Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 218. Rest of South America Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 219. Asia Pacific Chickenpox Vaccine, by Country USD Million (2023-2028)
  • Table 220. Asia Pacific Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 221. Asia Pacific Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 222. Asia Pacific Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 223. China Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 224. China Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 225. China Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 226. Japan Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 227. Japan Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 228. Japan Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 229. India Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 230. India Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 231. India Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 232. South Korea Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 233. South Korea Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 234. South Korea Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 235. Taiwan Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 236. Taiwan Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 237. Taiwan Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 238. Australia Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 239. Australia Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 240. Australia Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 241. Rest of Asia-Pacific Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 242. Rest of Asia-Pacific Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 243. Rest of Asia-Pacific Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 244. Europe Chickenpox Vaccine, by Country USD Million (2023-2028)
  • Table 245. Europe Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 246. Europe Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 247. Europe Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 248. Germany Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 249. Germany Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 250. Germany Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 251. France Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 252. France Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 253. France Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 254. Italy Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 255. Italy Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 256. Italy Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 257. United Kingdom Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 258. United Kingdom Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 259. United Kingdom Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 260. Netherlands Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 261. Netherlands Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 262. Netherlands Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 263. Rest of Europe Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 264. Rest of Europe Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 265. Rest of Europe Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 266. MEA Chickenpox Vaccine, by Country USD Million (2023-2028)
  • Table 267. MEA Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 268. MEA Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 269. MEA Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 270. Middle East Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 271. Middle East Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 272. Middle East Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 273. Africa Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 274. Africa Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 275. Africa Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 276. North America Chickenpox Vaccine, by Country USD Million (2023-2028)
  • Table 277. North America Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 278. North America Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 279. North America Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 280. United States Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 281. United States Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 282. United States Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 283. Canada Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 284. Canada Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 285. Canada Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 286. Mexico Chickenpox Vaccine, by Type USD Million (2023-2028)
  • Table 287. Mexico Chickenpox Vaccine, by Application USD Million (2023-2028)
  • Table 288. Mexico Chickenpox Vaccine, by End User USD Million (2023-2028)
  • Table 289. Chickenpox Vaccine Sales: by Type(K Units)
  • Table 290. Chickenpox Vaccine Sales Monovalent Vaccine , by Region K Units (2023-2028)
  • Table 291. Chickenpox Vaccine Sales Combination Vaccine , by Region K Units (2023-2028)
  • Table 292. Chickenpox Vaccine Sales: by Application(K Units)
  • Table 293. Chickenpox Vaccine Sales Hospitals , by Region K Units (2023-2028)
  • Table 294. Chickenpox Vaccine Sales Clinics , by Region K Units (2023-2028)
  • Table 295. Chickenpox Vaccine Sales Laboratories , by Region K Units (2023-2028)
  • Table 296. Chickenpox Vaccine Sales: by End User(K Units)
  • Table 297. Chickenpox Vaccine Sales Children , by Region K Units (2023-2028)
  • Table 298. Chickenpox Vaccine Sales Adults , by Region K Units (2023-2028)
  • Table 299. South America Chickenpox Vaccine Sales, by Country K Units (2023-2028)
  • Table 300. South America Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 301. South America Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 302. South America Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 303. Brazil Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 304. Brazil Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 305. Brazil Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 306. Argentina Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 307. Argentina Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 308. Argentina Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 309. Rest of South America Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 310. Rest of South America Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 311. Rest of South America Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 312. Asia Pacific Chickenpox Vaccine Sales, by Country K Units (2023-2028)
  • Table 313. Asia Pacific Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 314. Asia Pacific Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 315. Asia Pacific Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 316. China Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 317. China Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 318. China Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 319. Japan Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 320. Japan Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 321. Japan Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 322. India Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 323. India Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 324. India Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 325. South Korea Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 326. South Korea Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 327. South Korea Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 328. Taiwan Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 329. Taiwan Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 330. Taiwan Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 331. Australia Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 332. Australia Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 333. Australia Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 334. Rest of Asia-Pacific Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 335. Rest of Asia-Pacific Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 336. Rest of Asia-Pacific Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 337. Europe Chickenpox Vaccine Sales, by Country K Units (2023-2028)
  • Table 338. Europe Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 339. Europe Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 340. Europe Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 341. Germany Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 342. Germany Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 343. Germany Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 344. France Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 345. France Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 346. France Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 347. Italy Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 348. Italy Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 349. Italy Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 350. United Kingdom Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 351. United Kingdom Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 352. United Kingdom Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 353. Netherlands Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 354. Netherlands Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 355. Netherlands Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 356. Rest of Europe Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 357. Rest of Europe Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 358. Rest of Europe Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 359. MEA Chickenpox Vaccine Sales, by Country K Units (2023-2028)
  • Table 360. MEA Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 361. MEA Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 362. MEA Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 363. Middle East Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 364. Middle East Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 365. Middle East Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 366. Africa Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 367. Africa Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 368. Africa Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 369. North America Chickenpox Vaccine Sales, by Country K Units (2023-2028)
  • Table 370. North America Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 371. North America Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 372. North America Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 373. United States Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 374. United States Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 375. United States Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 376. Canada Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 377. Canada Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 378. Canada Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 379. Mexico Chickenpox Vaccine Sales, by Type K Units (2023-2028)
  • Table 380. Mexico Chickenpox Vaccine Sales, by Application K Units (2023-2028)
  • Table 381. Mexico Chickenpox Vaccine Sales, by End User K Units (2023-2028)
  • Table 382. Chickenpox Vaccine: by Type(USD/Units)
  • Table 383. Research Programs/Design for This Report
  • Table 384. Key Data Information from Secondary Sources
  • Table 385. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chickenpox Vaccine: by Type USD Million (2017-2022)
  • Figure 5. Global Chickenpox Vaccine: by Application USD Million (2017-2022)
  • Figure 6. Global Chickenpox Vaccine: by End User USD Million (2017-2022)
  • Figure 7. South America Chickenpox Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Chickenpox Vaccine Share (%), by Country
  • Figure 9. Europe Chickenpox Vaccine Share (%), by Country
  • Figure 10. MEA Chickenpox Vaccine Share (%), by Country
  • Figure 11. North America Chickenpox Vaccine Share (%), by Country
  • Figure 12. Global Chickenpox Vaccine: by Type K Units (2017-2022)
  • Figure 13. Global Chickenpox Vaccine: by Application K Units (2017-2022)
  • Figure 14. Global Chickenpox Vaccine: by End User K Units (2017-2022)
  • Figure 15. South America Chickenpox Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Chickenpox Vaccine Share (%), by Country
  • Figure 17. Europe Chickenpox Vaccine Share (%), by Country
  • Figure 18. MEA Chickenpox Vaccine Share (%), by Country
  • Figure 19. North America Chickenpox Vaccine Share (%), by Country
  • Figure 20. Global Chickenpox Vaccine: by Type USD/Units (2017-2022)
  • Figure 21. Global Chickenpox Vaccine share by Players 2022 (%)
  • Figure 22. Global Chickenpox Vaccine share by Players (Top 3) 2022(%)
  • Figure 23. Global Chickenpox Vaccine share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Biken Group (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Biken Group (Japan) Revenue: by Geography 2022
  • Figure 29. Green Cross Health Ltd. (New Zealand) Revenue, Net Income and Gross profit
  • Figure 30. Green Cross Health Ltd. (New Zealand) Revenue: by Geography 2022
  • Figure 31. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Novo (India) Revenue, Net Income and Gross profit
  • Figure 34. Novo (India) Revenue: by Geography 2022
  • Figure 35. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 37. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2022
  • Figure 39. The Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 40. The Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 41. Global Chickenpox Vaccine: by Type USD Million (2023-2028)
  • Figure 42. Global Chickenpox Vaccine: by Application USD Million (2023-2028)
  • Figure 43. Global Chickenpox Vaccine: by End User USD Million (2023-2028)
  • Figure 44. South America Chickenpox Vaccine Share (%), by Country
  • Figure 45. Asia Pacific Chickenpox Vaccine Share (%), by Country
  • Figure 46. Europe Chickenpox Vaccine Share (%), by Country
  • Figure 47. MEA Chickenpox Vaccine Share (%), by Country
  • Figure 48. North America Chickenpox Vaccine Share (%), by Country
  • Figure 49. Global Chickenpox Vaccine: by Type K Units (2023-2028)
  • Figure 50. Global Chickenpox Vaccine: by Application K Units (2023-2028)
  • Figure 51. Global Chickenpox Vaccine: by End User K Units (2023-2028)
  • Figure 52. South America Chickenpox Vaccine Share (%), by Country
  • Figure 53. Asia Pacific Chickenpox Vaccine Share (%), by Country
  • Figure 54. Europe Chickenpox Vaccine Share (%), by Country
  • Figure 55. MEA Chickenpox Vaccine Share (%), by Country
  • Figure 56. North America Chickenpox Vaccine Share (%), by Country
  • Figure 57. Global Chickenpox Vaccine: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • Biken Group (Japan)
  • Green Cross Health Ltd. (New Zealand)
  • GlaxoSmithKline plc. (United Kingdom)
  • Novo (India)
  • Sanofi S.A. (France)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • The Takeda Pharmaceutical Company Limited (Japan)
Select User Access Type

Key Highlights of Report


May 2023 201 Pages 51 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chickenpox Vaccine Quantitative research analysis
Global Chickenpox Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Chickenpox Vaccine Market are by type [Monovalent Vaccine and Combination Vaccine], by end use application [Hospitals, Clinics and Laboratories].
The Chickenpox Vaccine Market is gaining popularity and expected to see strong valuation by 2028.
  • Growing Health Awareness Across the World
  • Need for Preventive Vaccination from Contagious Diseases
  • Stringent Regulatory Guidelines Regarding Chickenpox

Know More About Global Chickenpox Vaccine Report?

Have a Query? Click Here

Other Related Reports

Addiction Treatment Comprehensive Study by Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, Other Substance Addiction Treatment), Drug Type (Buprop...
$ 3750
Atopic Dermatitis Treatment Comprehensive Study by Route of Administration (Oral, Topical, Injectable), Treatment (Medications, Wet Dressings, Light Therapy, Others), Distribution Channel (Hospital P...
$ 3750
Axial Spondyloarthritis Treatment Comprehensive Study by Type (COX-2 Antagonists, COX Inhibitors, Others), Application (Hospital, Rehabilitation Center, Other), Distribution Channel (Online, Medical ...
$ 3650
Carotid Endarterectomy Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centre, Others), Diagnosis (Computed Tomography Angiography, Carotid Ultrasound, Magnetic Resonance ...
$ 3500
Wilson's Disease Treatment Comprehensive Study by Type (Medication (Trientine, Penicillamine, Zinc Acatate), Surgery), Application (Hospitals, Specialty Clinics, Diagnostic Laboratories), Test Type (...
$ 3750
Myelodysplastic Syndrome Comprehensive Study by Type (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others), Application (Hospital, Clinic), Route of Administration (Generic, Or...
$ 3650